APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 2) Patient must have a diagnosis of pancreatic cancer and have successfully undergone a curative intent surgical resection and must have no evidence of recurrent disease as determined by the investigator. 3) Patient must have a known pathogenic or likely pathogenic germline or somatic mutation in BRCA1, BRCA2, or PALB2, as determined by a Clinical Laboratory Improvement Amendments (CLIA) certified or equivalently-accredited laboratory.

You may not be eligible for this study if the following are true:

  • 1) Patient has evidence of recurrent or metastatic pancreatic cancer at the time of randomization as documented by baseline scans obtained = 4 weeks prior to randomization. 2) Patient has previously had evidence of progressive pancreatic cancer while receiving platinum-based therapy. 3) Patient did not recover from any adverse events due to prior anti-cancer therapy (i.e., have no residual toxicities > Grade 1 with the exception of alopecia and/or neuropathy).


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.